Trastuzumab deruxtecan (T-DXd) has side effects that include but are not limited to interstitial lung disease/pneumonitis, nausea and vomiting, haematological toxicities, fatigue, hair loss, and cardiac toxicities.

A panel of 13 experts in oncology, pulmonology and radiology developed practical recommendations for monitoring and managing these T-DXd–related side effects applicable for Asia-Pacific clinical practice.

While subgroup analysis of Asian (excluding Japanese) versus overall population in the DESTINY-Breast03 clinical trial uncovered no major differences in the side effects profile, proactive monitoring and management are key to maximising the benefits conferred by T-DXd for patients with HER2-positive or HER2-low metastatic breast cancer.

Patient education on signs and symptoms of T-DXd–related side effects is also important for maximising the benefits with this treatment.